IL2 and COVID-19: Our results indicate that both naïve and COVID-19-recovered HD patients maintain strong cellular and humoral immune responses after receiving a third dose (booster), which is comparable or higher (significant increased at V3+3M for IFN-γ and IL-2) to HV individuals.